S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:QLGN

Qualigen Therapeutics - QLGN Stock Forecast, Price & News

$0.89
-0.01 (-0.67%)
(As of 03/28/2023 05:12 PM ET)
Add
Compare
Today's Range
$0.86
▼
$0.91
50-Day Range
$0.90
▼
$1.43
52-Week Range
$0.84
▼
$15.20
Volume
31,747 shs
Average Volume
407,397 shs
Market Capitalization
$3.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Qualigen Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
349.4% Upside
$4.00 Price Target
Short Interest
Healthy
1.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.47mentions of Qualigen Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.02) to ($4.33) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

See Top Rated MarketRank™ Stocks Here

QLGN stock logo

About Qualigen Therapeutics (NASDAQ:QLGN) Stock

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

Receive QLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

QLGN Stock News Headlines

March 21, 2023 | finanznachrichten.de
Qualigen Therapeutics, Inc.: Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office
March 21, 2023 | finance.yahoo.com
Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office
March 28, 2023 | The Oxford Club (Ad)
Unusual Passive Income Investment (Found on a Golf Course)
Marc reveals how anyone can get into a similar opportunity for just $5.
March 15, 2023 | finance.yahoo.com
Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023
March 9, 2023 | finance.yahoo.com
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference
March 8, 2023 | finance.yahoo.com
Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
February 1, 2023 | finance.yahoo.com
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
January 24, 2023 | finance.yahoo.com
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
March 28, 2023 | The Oxford Club (Ad)
Unusual Passive Income Investment (Found on a Golf Course)
Marc reveals how anyone can get into a similar opportunity for just $5.
January 23, 2023 | finance.yahoo.com
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications
January 10, 2023 | marketwatch.com
Qualigen Therapeutics' QN-302 Receives FDA's Orphan Drug Designation
January 10, 2023 | finance.yahoo.com
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
January 5, 2023 | finance.yahoo.com
Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
December 13, 2022 | finanznachrichten.de
Qualigen Therapeutics, Inc.: Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
December 12, 2022 | technews.tmcnet.com
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
December 7, 2022 | finance.yahoo.com
Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
December 1, 2022 | finance.yahoo.com
QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor…
November 22, 2022 | finance.yahoo.com
Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split
November 17, 2022 | finance.yahoo.com
Qualigen Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
November 15, 2022 | finance.yahoo.com
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 21, 2022 | seekingalpha.com
QLGN Qualigen Therapeutics, Inc.
October 19, 2022 | finance.yahoo.com
Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
October 18, 2022 | finance.yahoo.com
Qualigen Therapeutics to Present at LD Micro Main Event XV
October 6, 2022 | finance.yahoo.com
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
September 14, 2022 | finance.yahoo.com
Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
August 25, 2022 | finance.yahoo.com
QLGN: FastPack Sales Up 28% YoY…
August 18, 2022 | finance.yahoo.com
Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board
See More Headlines
Receive QLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

QLGN Company Calendar

Last Earnings
11/15/2021
Today
3/28/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QLGN
CUSIP
N/A
CIK
1460702
Web
www.qualigeninc.com
Phone
(760) 918-9165
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+346.4%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($5.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
-361.16%
Pretax Margin
N/A
Return on Equity
-103.59%
Return on Assets
-73.16%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.13
Quick Ratio
1.83

Sales & Book Value

Annual Sales
$5.65 million
Price / Sales
0.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.63 per share
Price / Book
0.16

Miscellaneous

Outstanding Shares
4,210,000
Free Float
3,941,000
Market Cap
$3.77 million
Optionable
Not Optionable
Beta
-0.41

Key Executives

  • Michael S. PoirierMichael S. Poirier
    Chairman & Chief Executive Officer
  • Amy S. BroidrickAmy S. Broidrick
    President, COO, Director & Chief Strategy Officer
  • Christopher L. Lotz
    Chief Financial Officer & Vice President
  • Wajdi Abdul-Ahad
    Chief Scientific Officer & Vice President-R&D
  • Tariq Arshad
    Chief Medical Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













QLGN Stock - Frequently Asked Questions

What is Qualigen Therapeutics' stock price forecast for 2023?

0 Wall Street analysts have issued 12-month price targets for Qualigen Therapeutics' shares. Their QLGN share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 346.4% from the stock's current price.
View analysts price targets for QLGN or view top-rated stocks among Wall Street analysts.

How have QLGN shares performed in 2023?

Qualigen Therapeutics' stock was trading at $1.2890 at the start of the year. Since then, QLGN stock has decreased by 30.5% and is now trading at $0.8960.
View the best growth stocks for 2023 here.

Are investors shorting Qualigen Therapeutics?

Qualigen Therapeutics saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 55,700 shares, a decline of 31.0% from the February 28th total of 80,700 shares. Based on an average daily trading volume, of 370,800 shares, the short-interest ratio is currently 0.2 days. Approximately 1.5% of the company's stock are short sold.
View Qualigen Therapeutics' Short Interest.

When is Qualigen Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our QLGN earnings forecast.

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced its earnings results on Monday, November, 15th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.10. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.50 million. Qualigen Therapeutics had a negative trailing twelve-month return on equity of 103.59% and a negative net margin of 361.16%.

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qualigen Therapeutics investors own include iBio (IBIO), Boeing (BA), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), NIO (NIO), NVIDIA (NVDA), Riot Platforms (RIOT), Vaxart (VXRT), Boxlight (BOXL) and Enphase Energy (ENPH).

What is Qualigen Therapeutics' stock symbol?

Qualigen Therapeutics trades on the NASDAQ under the ticker symbol "QLGN."

Who are Qualigen Therapeutics' major shareholders?

Qualigen Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.54%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amy S Broidrick, Christopher L Lotz, Kurt H Kruger, Kurt H Kruger and Michael S Poirier.
View institutional ownership trends.

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Qualigen Therapeutics' stock price today?

One share of QLGN stock can currently be purchased for approximately $0.90.

How much money does Qualigen Therapeutics make?

Qualigen Therapeutics (NASDAQ:QLGN) has a market capitalization of $3.77 million and generates $5.65 million in revenue each year.

How can I contact Qualigen Therapeutics?

Qualigen Therapeutics' mailing address is 2042 Corte Del Nogal, Carlsbad CA, 92011. The official website for the company is www.qualigeninc.com. The company can be reached via phone at (760) 918-9165 or via email at ybriggs@lhai.com.

This page (NASDAQ:QLGN) was last updated on 3/28/2023 by MarketBeat.com Staff